Article

Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial.

Division of Head and Neck, Cancer Institute Hospital, Koto-ku, Tokyo, Japan.
The Journal of clinical endocrinology and metabolism (impact factor: 6.5). 10/2010; 95(10):4576-83. DOI:10.1210/jc.2010-0161 pp.4576-83
Source: PubMed

ABSTRACT TSH suppression therapy has been used to decrease thyroid cancer recurrence. However, validation of effects through studies providing a high level of evidence has been lacking.
This single-center, open-label, randomized controlled trial tested the hypothesis that disease-free survival (DFS) for papillary thyroid carcinoma (PTC) in patients without TSH suppression is not inferior to that in patients with TSH suppression.
Participants were randomly assigned to receive postoperative TSH suppression therapy (group A) or not (group B). Before assignment, patients were stratified into groups with low- and high-risk PTC according to the AMES (age, metastasis, extension, size) risk-group classification.
For patients assigned to group A, L-T(4) was administered to keep serum TSH levels below 0.01 μU/ml. TSH levels were adjusted to within normal ranges for patients assigned to group B. Recurrence was evaluated by neck ultrasonography and chest computed tomography.
Eligible participants were recruited from 1996-2005, with 218 patients assigned to group A and 215 patients to group B. Analysis was performed on an intention-to-treat basis. DFS did not differ significantly between groups. The 95% confidence interval of the hazard ratio for recurrence was 0.85-1.27 according to Cox proportional hazard modeling, within the margin of 2.12 required to declare 10% noninferiority.
DFS for patients without TSH suppression was not inferior by more than 10% to DFS for patients with TSH suppression. Thyroid-conserving surgery without TSH suppression should be considered for patients with low-risk PTC to avoid potential adverse effects of TSH suppression.

0 0
 · 
0 Bookmarks
 · 
27 Views
  • Source
    Article: Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma.
    Katsuhiro Tanaka, Hiroshi Sonoo, Wataru Saito, Yusuke Ohta, Toshiro Shimo, Mai Sohda, Yutaka Yamamoto, Junichi Kurebayashi
    [show abstract] [hide abstract]
    ABSTRACT: Background. We retrospectively analyzed whether poor differentiation is the independent prognostic factor for thyroid carcinoma or not. Methods. The subjects were 29 patients with PDTC who were treated between April 1996 and March 2006 to compare with those of well-differentiated papillary carcinoma patients (n = 227). Results. The relapse free (RFS), distant relapse-free survival and cause-specific survival, rates were significantly lower in patients with PDTC (P < .0001, P < .001, and P < .05). After classification into focal (<10%) and diffuse type (over 10%) of PDTC, there were no significant differences in RFS and cause-specific survival due to component type or proportion of poorly differentiated component. On multivariate analysis, poor differentiation (P < .0005, RR = 4.456, 95% CI; 1.953-10.167) and extrathyroidal infiltration (P < .05, RR = 2.898, 95% CI; 1.278-6.572) showed a significant impact on DFS, and poor differentiation (P < .05, RR = 9.343, 1.314-66.453) and age (P < .005, RR = 1.306, 1.103-1.547) significantly impacted cause-specific survival. Conclusion. Poor differentiation was an independent factor for survival. Distant relapse was significantly more common among PDTC patients, and systemic therapy might be warranted.
    ISRN endocrinology. 01/2011; 2011:308029.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

95% confidence interval
 
chest computed tomography
 
Cox proportional hazard modeling
 
decrease thyroid cancer recurrence
 
disease-free survival
 
Eligible participants
 
group B
 
group B. Analysis
 
group B. Recurrence
 
hazard ratio
 
high-risk PTC
 
intention-to-treat basis
 
neck ultrasonography
 
normal ranges
 
open-label
 
postoperative TSH suppression therapy
 
serum TSH levels
 
TSH levels
 
TSH suppression
 
TSH suppression therapy